Objective: To study the clinical efficacy and possible mechanism of bifidobacterium triple live bacteria capsules combined with Shanbai Xiaoshi mixture in the treatment of dyspeptic diarrhea. Methods: A total of 140 children with dyspeptic diarrhea in the pediatric outpatients of Xuzhou Children’s Hospital from Jan. 2017 to Jun. 2019 were extracted to be divided into the control group and the experimental group via the random number table

with 70 cases in each group. The control group was treated with with Shanbai Xiaoshi mixture

while the experimental group received bifidobacterium triple live bacteria capsules on the basis of the control group. Both groups were treated for 14 d. The disappearance time of major clinical symptoms

clinical efficacy

adverse drug reactions

serum inflammatory factors before and after treatment

and glycocalyx-related indicators of two groups were compared. Results: The antipyretic time

disappearance time of abdominal pain and diarrhea

and disappearance time of vomiting in the experimental group were shorter than those in the control group (P<0.05). The total effective rate was 78.57% in the control group and 97.14% in the experimental group (P<0.05); the incidence of adverse drug reactions was 5.71% in the control group and 10.00% in the experimental group (P>0.05). After treatment

the levels of tumor necrosis factor (TNF)-α

interleukin (IL)-6 and IL-17 in two groups decreased compared with those before treatment

the levels of TNF-α

IL-6 and IL-17 in the experimental group were significantly lower than those in the control group (P<0.05). After treatment

the levels of serum heparan sulfate

Syndecan-1 and hyaluronic acid in two groups were lower than those before treatment

the levels of serum Syndecan-1 and hyaluronic acid in the experimental group were significantly lower than those in the control group (P<0.01). Conclusion: The clinical efficacy of bifidobacterium triple live bacteria capsules combined with Shanbai Xiaoshi mixture in the treatment of dyspeptic diarrhea is significant

which can improve the dyspeptic diarrhea and promote the improvement of clinical symptoms by inhibiting the shedding and degradation of endothelial glycocalyx and reducing the level of serum inflammatory factors.